Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May;55(3):213-223.
doi: 10.1002/lipd.12230. Epub 2020 Mar 2.

Plasma Ceramides and Sphingomyelins of Pediatric Patients Increase in Primary Ciliary Dyskinesia but Decrease in Cystic Fibrosis

Dilara Bal Topçu  1 , Gokcen Tugcu  2 , Filiz Ozcan  3 , Mutay Aslan  3 , Ahmet Yalcinkaya  1 , Sanem Eryilmaz Polat  2 , Mina Hizal  2 , Ebru Elmas Yalcin  2 , Deniz Dogru Ersoz  2 , Ugur Ozcelik  2 , Nural Kiper  2 , Incilay Lay  1 , Yesim Oztas  1
Affiliations

Plasma Ceramides and Sphingomyelins of Pediatric Patients Increase in Primary Ciliary Dyskinesia but Decrease in Cystic Fibrosis

Dilara Bal Topçu et al. Lipids. 2020 May.

Abstract

We investigated plasma sphingomyelin (CerPCho) and ceramide (Cer) levels in pediatric patients with cystic fibrosis (CF) and primary ciliary dyskinesia (PCD). Plasma samples were obtained from CF (n = 19) and PCD (n = 7) patients at exacerbation, discharge, and stable periods. Healthy children (n = 17) of similar age served as control. Levels of 16-24 CerPCho and 16-24 Cer were measured by LC-MS/MS. Concentrations of all CerPCho and Cer species measured at exacerbation were significantly lower in patients with CF than PCD. 16, 18, 24 CerPCho, and 22, 24 Cer in exacerbation; 18, 24 CerPCho, and 18, 20, 22, 24 Cer at discharge; 18, 24 CerPCho and 24 Cer at stable period were significantly lower in CF patients than healthy children (p < 0.001 and p < 0.05). All CerPCho and Cer levels of PCD patients were significantly higher except 24 CerPCho and 24 Cer during exacerbation, 24 CerPCho at discharge, and 18, 22 CerPCho levels at stable period (p < 0.001 and p < 0.05) compared with healthy children. There was no significant difference among exacerbation, discharge, and stable periods in each group for Cer and CerPCho levels. This is the first study measuring plasma Cer and CerPCho levels in PCD and third study in CF patients. The dramatic difference in plasma levels of most CerPCho and Cer species found between two diseases suggest that cilia pathology in PCD and CFTR mutation in CF seem to alter sphingolipid metabolism possibly in opposite directions.

Keywords: Ceramide; Cystic fibrosis; Inflammation; Primary ciliary dyskinesia; Sphingolipid; Sphingomyelin.

PubMed Disclaimer

References

    1. Adada, M., Luberto, C., & Canals, D. (2016) Inhibitors of the sphingomyelin cycle: Sphingomyelin synthases and sphingomyelinases. Chemistry and Physics of Lipids, 197:45-59.
    1. Andrieu-Abadie, N., Gouaze, V., Salvayre, R., & Levade, T. (2001) Ceramide in apoptosis signaling: Relationship with oxidative stress. Free Radical Biology & Medicine, 31:717-728.
    1. Aslan, M., Kirac, E., Kaya, S., Ozcan, F., Salim, O., & Kupesiz, O. A. (2018) Decreased serum levels of sphingomyelins and ceramides in sickle cell disease patients. Lipids, 53:313-322.
    1. Aureli, M., Schiumarini, D., Loberto, N., Bassi, R., Tamanini, A., Mancini, G., … Sonnino, S. (2016) Unravelling the role of sphingolipids in cystic fibrosis lung disease. Chemistry and Physics of Lipids, 200:94-103.
    1. Barasch, J., Kiss, B., Prince, A., Saiman, L., Gruenert, D., & Al-Awqati, Q. (1991) Defective acidification of intracellular organelles in cystic fibrosis. Nature, 352:70-73.

Publication types

LinkOut - more resources